Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, is being tested in persons with early Alzheimer’s disease. We conducted an 18-month ...

The drug, called lecanemab, reduced the rate of cognitive decline by 27% in a study of nearly 1,800 people in the early stages of Alzheimer's, scientists reported at the Clinical Trials on ...

The drug, a monoclonal antibody called lecanemab, dominated last week's Clinical Trials on Alzheimer's Disease meeting in San Francisco. At the meeting, researchers presented results of a study of ...

Lecanemab will be marketed as Leqembi, the FDA statement said. It has shown “potential” as an Alzheimer’s disease treatment by appearing to slow progression, according to Phase 3 trial ...

Lecanemab (brand name: Leqembi), made by Eisai and Biogen, was granted accelerated FDA approval in Jan. 2023 based on early-stage studies of the drug’s effectiveness, and the companies submitted ...

However, a new study has shown that two drugs - lecanemab and donanemab - could help patients stay independent by approximately 10-13 months in the early stage. Usually, in Alzheimer's disease ...

New research shows that lecanemab and donanemab can slow cognitive decline and extend patients' independence in daily activities. But with high costs and risks, are these treatments truly ...

The treatment, lecanemab, was found to triple the risk of death within a year, compared with dementia sufferers not prescribed the drug. Previous studies have suggested it slowed the progression ...

Although 23 enrollees withdrew, no macrohemorrhages or deaths were recorded. Treatment with lecanemab infusion was safe and generally well-tolerated within an outpatient memory clinic setting ...

Lecanemab, the disease-modifying drug which can slow down the progression of Alzheimer’s disease, is set to be one of the most sought-after medications in the country after UK regulators ...

A resident of a nursing home plays the game "Memory" on a care ward and puts pairs of cards together. The European Commission has approved the antibody lecanemab to treat Alzheimer's, the first ...

A Prescription Drug User Fee Act target date of August 31, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...